ResearcherFox Chase Cancer CenterNo recent work listed
Neal J. Meropol
Matched on ORCID iD 0000-0001-6353-7364; OpenAlex author ID A5053128814. Sources: ClinicalTrials.gov.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 2
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2000: 2 trials · 2001: none · 2002: none · 2003: none · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 1 paper · 2012: none · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper
Papers 4
- Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000619↗
- Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value. Co-author DOI 10.14694/edbook_am.2015.35.e222↗
- Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advan… Co-author DOI 10.1016/j.radonc.2014.08.014↗
- Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcin… First author DOI 10.1097/coc.0b013e3181d2734a↗
Trials 2
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Steven J. Cohen · 3 shared papers, 2011–2016 · strength 0.11
- Paper Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma. DOI 10.1097/mpa.0000000000000619↗
- Paper Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and … DOI 10.1016/j.radonc.2014.08.014↗
- Paper Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously t… DOI 10.1097/coc.0b013e3181d2734a↗
- Michael J. Hall · 2 shared papers, 2014–2016 · strength 0.09
- Paper Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma. DOI 10.1097/mpa.0000000000000619↗
- Paper Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and … DOI 10.1016/j.radonc.2014.08.014↗
- Igor A. Astsaturov · 2 shared papers, 2011–2016 · strength 0.08
- Paper Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma. DOI 10.1097/mpa.0000000000000619↗
- Paper Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously t… DOI 10.1097/coc.0b013e3181d2734a↗
- Andrew H. Ko · 1 shared paper, 2015 · strength 0.07
- Daniel H. Ahn · 1 shared paper, 2015 · strength 0.07
- Tanios Bekaii‐Saab · 1 shared paper, 2015 · strength 0.07
- Efrat Dotan · 1 shared paper, 2016 · strength 0.05
- Andre A. Konski · 1 shared paper, 2014 · strength 0.04
- Joshua E. Meyer · 1 shared paper, 2014 · strength 0.04
- Minsig Choi · 1 shared paper, 2014 · strength 0.04
- Anthony Frank Shields · 1 shared paper, 2014 · strength 0.04
- Philip A. Philip · 1 shared paper, 2014 · strength 0.04
- Jonathan D. Cheng · 1 shared paper, 2011 · strength 0.02
- Barbara Ann Burtness · 1 shared paper, 2011 · strength 0.02
- Louis M. Weiner · 1 shared paper, 2011 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.